Workflow
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
GlobeNewswire News Room· 2025-02-04 12:30
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET.   A webcast of Sensei’s presentation will be available in the Investor ...
PSEG To Announce Fourth Quarter and Full Year 2024 Financial Results On February 25
Prnewswire· 2025-02-04 12:30
NEWARK, N.J., Feb. 4, 2025 /PRNewswire/ -- Public Service Enterprise Group Incorporated (PSEG) will host its fourth quarter and full year 2024 earnings call at 11:00 a.m. ET on Tuesday, February 25, during which management will discuss fourth quarter and year end financial results, financial guidance, capital investments, regulatory activities, and other important matters.The audio webcast can be accessed at that time, along with accompanying presentation materials, on the Investor News and Events section o ...
Appia Announces Excellent Desorption Results From Its Four New Ionic Adsorption Clay Targets at the PCH Project in Goias, Brazil
Newsfile· 2025-02-04 12:30
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQB: APAAF) (FWB: A0I0) (MUN: A0I0) (BER: A0I0) (the "Company" or "Appia")  announces updated results from the Ionic Adsorption Clay (IAC) rare earth elements (REE) targets Maia, Electra, Taygeta and Merope at the PCH project (Map 1). (See August 20th, 2024 Press Release - Click Here) A total of 1,173 samples from 163 Auger drillholes were tested and confirm the presence of extensive IAC style REE minera ...
Dell: Recent Weakness Provides A Compelling Buying Opportunity
Seeking Alpha· 2025-02-04 12:30
Dell Technologies (NYSE: DELL ) stock has underperformed the broader stock market since my previous 'Strong buy' recommendation . Short-term market movements might be unfair, which is highly likely is our case. I think that the market isComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analysis of public companies paid off and n ...
ZenaTech Signes LOI to Acquire a Fifth Land Survey Company; Focused on Assisting Border Patrol and Law Enforcement to Control Illegal Immigration
GlobeNewswire News Room· 2025-02-04 12:30
VANCOUVER, British Columbia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces that it has signed an LOI (Letter of Intent) to acquire a fifth land survey engineering company located in Southeast Florida. Upon completion, this will be the second acquisition in the Southeast, adding to the Company’s na ...
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire News Room· 2025-02-04 12:30
EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually, February 11-12, 2025. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will participate in a fireside chat on Tuesday, February 11, 2025 at 3:20 PM ET. The presentation can be assessed by visiting https ...
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Prnewswire· 2025-02-04 12:30
CUPERTINO, Calif., Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, to be held virtually, February 11-12, 2025.Presentation details are as follows: Date and time:         Tue, Feb 11 at 2:00-2:30 PM ET (Track 5) Webcast:                 https://wsw.com/webcast/oppenheimer39/drrx/2823424 DURECT management will participate in on ...
Soligenix to Present at BIO CEO & Investor Conference
Prnewswire· 2025-02-04 12:30
PRINCETON, N.J., Feb. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the BIO CEO & Investor Conference. The conference will be held February 10 - 11, 2025 in New York, N.Y. For more information about the BIO CEO & Investor Conference, please refer to ...
CME Group Reports Record January ADV of 25.7 Million Contracts
Prnewswire· 2025-02-04 12:30
Record January ADV for energy, agricultural and cryptocurrency products Record January ADV in U.S. Treasury futures and optionsCHICAGO, Feb. 4, 2025 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today reported its January 2025 market statistics reached 25.7 million contracts, the highest January average daily volume (ADV) on record, up 2% year-over-year. Market statistics are available in greater detail at https://cmegroupinc.gcs-web.com/monthly-volume.January 2025 ADV across asse ...
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Newsfile· 2025-02-04 12:27
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 04, 2025 7:27 AM EST | Source: Cardiol Therapeutics Inc.Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that ...